ALPHAMAB-B Shares Surge as Key Research Findings Selected for Prestigious 2026 ASCO Conference

Stock News

May 26

ALPHAMAB-B (09966) saw its share price rise over 8% during the trading session. As of the latest update, the stock was up 7.06%, trading at HKD 10.01 with a turnover of HKD 23.12 million.

The company previously announced that the Phase I clinical study results for JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate (ADC) for the treatment of HER2-negative locally advanced or metastatic breast cancer, have been selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The findings will be disclosed in a poster presentation during the conference.

Furthermore, significant results from the Phase III clinical study of anitumab (KN026), a HER2 bispecific antibody developed in collaboration with a wholly-owned subsidiary of CSPC Pharmaceutical Group, combined with CSPC's albumin-bound docetaxel (HB1801) for the neoadjuvant treatment of breast cancer, have been successfully selected for the "Late-Breaking Abstract" (LBA) session at the 2026 ASCO Annual Meeting.

The 2026 ASCO Annual Meeting is scheduled to take place from May 29 to June 2 in Chicago, USA.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1188952795"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1188952795\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1188952795?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-26 15:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188952795","market":"sg","top_or_hot":-1,"title":"ALPHAMAB-B Shares Surge as Key Research Findings Selected for Prestigious 2026 ASCO Conference","media":"Stock News","content":"<p>ALPHAMAB-B (09966) saw its share price rise over 8% during the trading session. As of the latest update, the stock was up 7.06%, trading at HKD 10.01 with a turnover of HKD 23.12 million.</p>\n<p>The company previously announced that the Phase I clinical study results for JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate (ADC) for the treatment of HER2-negative locally advanced or metastatic breast cancer, have been selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The findings will be disclosed in a poster presentation during the conference.</p>\n<p>Furthermore, significant results from the Phase III clinical study of anitumab (KN026), a HER2 bispecific antibody developed in collaboration with a wholly-owned subsidiary of CSPC Pharmaceutical Group, combined with CSPC's albumin-bound docetaxel (HB1801) for the neoadjuvant treatment of breast cancer, have been successfully selected for the \"Late-Breaking Abstract\" (LBA) session at the 2026 ASCO Annual Meeting.</p>\n<p>The 2026 ASCO Annual Meeting is scheduled to take place from May 29 to June 2 in Chicago, USA.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ALPHAMAB-B Shares Surge as Key Research Findings Selected for Prestigious 2026 ASCO Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nALPHAMAB-B Shares Surge as Key Research Findings Selected for Prestigious 2026 ASCO Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-26 15:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ALPHAMAB-B (09966) saw its share price rise over 8% during the trading session. As of the latest update, the stock was up 7.06%, trading at HKD 10.01 with a turnover of HKD 23.12 million.</p>\n<p>The company previously announced that the Phase I clinical study results for JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate (ADC) for the treatment of HER2-negative locally advanced or metastatic breast cancer, have been selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The findings will be disclosed in a poster presentation during the conference.</p>\n<p>Furthermore, significant results from the Phase III clinical study of anitumab (KN026), a HER2 bispecific antibody developed in collaboration with a wholly-owned subsidiary of CSPC Pharmaceutical Group, combined with CSPC's albumin-bound docetaxel (HB1801) for the neoadjuvant treatment of breast cancer, have been successfully selected for the \"Late-Breaking Abstract\" (LBA) session at the 2026 ASCO Annual Meeting.</p>\n<p>The 2026 ASCO Annual Meeting is scheduled to take place from May 29 to June 2 in Chicago, USA.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09966","symbol_name":"康宁杰瑞制药-B","start_time":0,"source_url":"","article_id":"1188952795","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188952795","pubTimestamp":1779781229,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ALPHAMAB-B (09966) saw its share price rise over 8% during the trading session. As of the latest update, the stock was up 7.06%, trading at HKD 10.01 with a turnover of HKD 23.12 million. The company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09966":"康宁杰瑞制药-B","BK4588":"碎股","BK1161":"生物科技","BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股","VXUS":"国际股票ETF-Vanguard"},"translate_title":"随着关键研究成果入选著名的2026年ASCO会议，ALPHAMAB-B股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"09966":1},"content_text":"ALPHAMAB-B (09966) saw its share price rise over 8% during the trading session. As of the latest update, the stock was up 7.06%, trading at HKD 10.01 with a turnover of HKD 23.12 million.\nThe company previously announced that the Phase I clinical study results for JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate (ADC) for the treatment of HER2-negative locally advanced or metastatic breast cancer, have been selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The findings will be disclosed in a poster presentation during the conference.\nFurthermore, significant results from the Phase III clinical study of anitumab (KN026), a HER2 bispecific antibody developed in collaboration with a wholly-owned subsidiary of CSPC Pharmaceutical Group, combined with CSPC's albumin-bound docetaxel (HB1801) for the neoadjuvant treatment of breast cancer, have been successfully selected for the \"Late-Breaking Abstract\" (LBA) session at the 2026 ASCO Annual Meeting.\nThe 2026 ASCO Annual Meeting is scheduled to take place from May 29 to June 2 in Chicago, USA.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}